Abstracts tagged "Biologic agents"

Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 2841 • 2013 ACR/ARHP Annual Meeting
Inflammation and Structural Progression In The Sacroiliac Joints Of Patients With Axial Spa Treated With Adalimumab Or Placebo As Assessed By The Berlin and The Spondyloarthritis Research Consortium Of Canada MRI Methods
Susanne Juhl Pedersen¹, Denis Poddubnyy², Inge Juul Sørensen³, Anne Gitte Loft⁴, Jens Skjødt Hindrup⁵, Gorm Thamsborg⁶, Karsten Asmussen⁷, Elka Kluger⁸, Jesper Nørregaard⁹, Torben Grube Christensen¹⁰, Anne G. Jurik¹¹, J.M. Møller¹², Thomas Skjødt¹³, Dorrit Mikkelsen¹⁴ and Mikkel Østergaard¹⁵, ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology, Hvidovre Hospital, Copenhagen, Denmark, ⁴Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ⁵Dep. of Rheumatology, Gentofte Hospital, Copenhagen, Denmark, ⁶Dep. of Rheumatology, Glostrup Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁸King Christian 10th Rheumatism Hospital at Gråsten, Graasten, Denmark, ⁹Dep of Rheumatology, Hørsholm Hospital, Hørsholm, Denmark, ¹⁰MD, Slagelse, Denmark, ¹¹Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ¹²Department of Radiology, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, ¹³Dep. of Radiology, Vejle Hospital, Vejle, Denmark, ¹⁴Dep. of Radiology, Aabenraa Hospital, Aabenraa, Denmark, ¹⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: To investigate changes in inflammation and structural progression in the sacroiliac joints (SIJs) in patients with axial spondyloarthritis (SpA) during treatment with adalimumab and…
Abstract Number: 2013 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Sarcoidosis. Multicenter Study Of 16 Patients
Javier Loricera¹, Vanesa Calvo-Río², Ricardo Blanco³, Marina Mesquida⁴, Alfredo M. Adan⁴, JM Herreras⁵, A Aparicio⁶, MJ Moreno Ramos⁷, MJ Moreno Martínez⁷, LF Linares Ferrando⁷, M Hernández Martínez⁸, D Peitado-Lopez⁹, Miguel Cordero-Coma¹⁰, Jl García Serrano¹¹, Norberto Ortego¹¹, O Maíz¹², A Blanco¹³, Juan Sánchez-Bursón¹⁴, S González-Suárez¹⁵, Alejandro Fonollosa¹⁶, Montserrat Santos-Gómez², F. Ortiz-Sanjuán¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁵Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ⁷Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ⁸Ophthalmology, Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ⁹Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ¹⁰Ophthalmology, Hospital de León. Spain, León, Spain, ¹¹Hospital San Cecilio. Granada, Granada, Spain, ¹²Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹³Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁴Hospital de Valme. Sevilla, Sevilla, Spain, ¹⁵Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ¹⁶Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain
Background/Purpose: Uveitis related to sarcoidosis is a potentially severe complication. Corticosteroids are the first line of treatment. In refractory cases or in those with unacceptable…
Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Arthur Kavanaugh¹, Susan J. Lee^2,3, Daniel H. Solomon⁴, Jeffrey D. Greenberg⁵, Joel M. Kremer⁶, Lilian Soto⁷, Carol J. Etzel^8,9 and George W. Reed¹⁰, ¹University of California, San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³San Diego Veterans Affairs Medical Center, San Diego, CA, ⁴Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁵NYU Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY, ⁷University of California San Diego, San Diego, CA, ⁸Department of Epidemiology, UT MD Anderson, Houston, TX, ⁹PO Box 786, Corrona, LLC., Southborough, MA, ¹⁰Corrona, LLC., Southborough, MA
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…
Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting
Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Louis Bessette¹, Denis Choquette², Diane Sauvageau³, Boulos Haraoui⁴, Jean Pierre Pelletier², Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal², ¹Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Bruno Fautrel¹, Thao Pham², Jacques Morel³, Toni Alfaiate⁴, Emmanuelle Dernis⁵, Philippe Gaudin⁶, Olivier Brocq⁷, Elisabeth Solau-Gervais⁸, Jean-Marie Berthelot⁹, Jean-Charles Balblanc¹⁰, Xavier Mariette¹¹ and Florence Tubach¹², ¹Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Le Mans Hospital, Le Mans, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Hospital of Princesse Grâce de Monaco, Monaco, France, ⁸Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁹Rheumatology Unit, Nantes University Hospital, Nantes, France, ¹⁰Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹²INSERM, Universite Paris Diderot, Paris, France
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 2028 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Adult-Onset Still’s Disease: A Long-Term Follow-Up Of 19 Patients At a Single Referral Center
Giulio Cavalli^1,2, Stefano Franchini¹, Alvise Berti¹, Corrado Campochiaro¹, Barbara Guglielmi¹, Maria Grazia Sabbadini¹, Elena Baldissera³ and Lorenzo Dagna^4,5, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²San Raffaele Scientific Institute, Milan, Italy, ³Vita-Salute San Raffaele University, Milano, Italy, ⁴Vita-Salute San Raffaele University, Milan, Italy, ⁵Medicine and Clinical Immunology, San Raffaele Scientific Institute, Milan, Italy
Background/Purpose: No data comparing the long-term outcome of Adult-Onset Still’s Disease (AOSD) patients treated with different biological drugs is currently available. We evaluated the efficacy…
Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Takao Koike¹, Masayoshi Harigai², Naoki Ishiguro³, Shigeko Inokuma⁴, Junnosuke Ryu⁵, Syuji Takei⁶, Tsutomu Takeuchi⁷, Y. Tanaka⁸, Masahiko Watanabe⁹ and Hisashi Yamanaka¹⁰, ¹Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Department of Allergy and Rheumatology diseases, Japanese Red Cross Medical Center, Tokyo, Japan, ⁵Nihon University School of Medicine, Tokyo, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Bristol-Myers K.K, Tokyo, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…
Abstract Number: 411 • 2013 ACR/ARHP Annual Meeting
Differential Effects of biologics On The Removal Of Amyloid Deposition Between The Kidney and Gastric Tract Of Amyloid A Amyloidosis Patients With Rheumatoid Arthritis
Hiroshi Uda¹, Tamaki Harada², Ayumi Matsumoto³, Aya Mizumoto², Toshirou Takama² and Osamu Saiki¹, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan, ³Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: Several biologics therapy reportedly regress gastric amyloid deposition in amyloid A (AA) amyloidosis patients with rheumatoid arthritis (RA), but it is uncertain whether the…
Abstract Number: 2484 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Michael Zisapel Zisapel¹, Noa Madar-Balakirsi², Hagit Padova³, Irena Wigler⁴, Daphna Paran⁵, Uri Arad⁴, Dan Caspi⁶ and Ori Elkayam⁷, ¹Rheumatology, Tel Aviv Medical Centet, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: TNFα blockers have been shown to produce immunogenecity in patients with rheumatoid arthritis, spondyloarthrritis and inflammatory bowel diseases. Data on the induction of anti-drug…
Abstract Number: 1942 • 2013 ACR/ARHP Annual Meeting
Ultrasound Shows Tenosynovitis to be Frequently Present as Well As Sensitive to Change in RA Patients On Biologic Medication
Hilde B. Hammer, Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for examination of tenosynovitis in patients with rheumatoid arthritis (RA). The…
Abstract Number: 1379 • 2013 ACR/ARHP Annual Meeting
Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes
Toshihiro Tono¹, Yoshiyuki Arinuma², Tatsuo Nagai³, Sumiaki Tanaka² and Shunsei Hirohata², ¹Int Med/Rheumatol & Infec Dis, Kitasato University school of medicine, sagamihara, Japan, ²Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ³Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Biological agents inhibiting proinflammatory cytokines, especially IL-6 and TNFa, have brought a great impact in the treatment of rheumatoid arthritis (RA). In addition, CTLA4-Ig…
Abstract Number: 415 • 2013 ACR/ARHP Annual Meeting
Stability Of Carotid Intima Media Thickness and No Plaque Formation In Inflammatory Arthritis Patients On Biologics Over One Year
Stephanie O. Keeling¹, Asvina Bissonauth², Jeff Odenbach², Quazi Ibrahim³ and Michael Sean McMurtry⁴, ¹Division of Rheumatology, Department of Medicine, University of Alberta, Canada, Edmonton, AB, Canada, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Medicine, EPICORE, Edmonton, AB, Canada, ⁴Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Carotid intima media (cIMT) measurement is a validated surrogate measure of cardiovascular (CV) disease. Our aim was to evaluate baseline and follow-up cIMTs in…
Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting
Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101
Limin Shang¹, Greg Elson¹, Jeremy Sokolove², Iain B. McInnes³, James Reilly⁴, Eric Hatterer¹, Marie Kosco-Vilbois⁵, Walter Ferlin⁵, Emmanuel Monnet⁵ and Cristina de Min⁶, ¹NovImmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵NovImmune S.A., Geneva, Switzerland, ⁶Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland
Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…
Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Francisco Ortiz-Sanjuan¹, Vanesa Calvo-Río², Ricardo Blanco³, Emma Beltrán⁴, Juan Sánchez-Bursón⁵, Marina Mesquida⁶, Alfredo M. Adan⁶, M Hernandez Grafella⁷, E Valls Pascual⁸, L Martínez-Costa⁹, Agustí Sellas-Fernàndez¹⁰, Miguel Cordero-Coma¹¹, Manuel Diaz-llopis¹², David Salom¹², Jl García Serrano¹³, Norberto Ortego¹³, JM Herreras¹⁴, Alejandro Fonollosa¹⁵, A Aparicio¹⁶, O Maíz¹⁷, A Blanco¹⁸, I Torre¹⁹, Cruz Fernández-Espartero²⁰, V Jovani²¹, D Peitado-Lopez²², Esperanza Pato²³, J Cruz²⁴, J. Carlos Fernandez-Cid²⁵, E. Aurrecoechea²⁶, M García²⁷, M Caracuel²⁸, Carlos Montilla²⁹, A Atanes³⁰, F Francisco³¹, S Insua³², S González-Suárez³³, A Sánchez-Andrade³⁴, F Gamero³⁵, Luis Linares³⁶, F Romero-Bueno³⁷, AJ García González³⁸, Raquel Almodovar³⁹, E Minguez⁴⁰, C Carrasco Cubero⁴¹, Alejandro Olive Marques⁴², J Vázquez⁴³, O Ruiz Moreno⁴⁴, F Jimenez-Zorzo⁴⁴, J Manero⁴⁴, Javier Loricera¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Hospital Marques de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁵Hospital de Valme. Sevilla, Sevilla, Spain, ⁶Ophthalmology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital General Universitario, Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Peset Valencia, Valencia, Spain, ⁹Ophthalmology, Hospital Peset Valencia, Valencia, Spain, ¹⁰Rheumatology, Hospital Val d´Hebron. Barcelona, Barcelona, Spain, ¹¹Departament of Ophthalmology, Hospital de León, León, Spain, ¹²Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain, ¹³Hospital San Cecilio. Granada, Granada, Spain, ¹⁴Hospital Universitario, IOBA. Valladolid, Valladolid, Spain, ¹⁵Ophtalmology Service, Hospital de Cruces. Bilbao, Bilbao, Spain, ¹⁶Rheumatology., Hospital de Toledo., Toledo, Spain, ¹⁷Rheumatology, Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁸Ophthalmology., Hospital Donosti San Sebastian, San Sebastián, Spain, ¹⁹Rheumatology., Hospital Basurto. Bilbao, Bilbao, Spain, ²⁰Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, ²¹Rheumatology., Hospital General de Alicante., Alicante, Spain, ²²Rheumatology, Hospital Universitario La Paz Madrid, Madrid, Spain, ²³Rheumatology, Hospital Clínico San Carlos. Madrid, Madrid, Spain, ²⁴Rheumatology, Hospital de Pontevedra, Pontevedra, Spain, ²⁵Departament of Ophthalmology, Hospital de Pontevedra, Pontevedra, Spain, ²⁶Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁷Rheumatology., Hospital La Princesa. Madrid, Madrid, Spain, ²⁸Rheumatology., Hospital de Córdoba., Córdoba, Spain, ²⁹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ³⁰Rheumatology., HUCA La Coruña., A Coruña, Spain, ³¹Rheumatology., Hospital Doctor Negrín Canarias., Canarias, Spain, ³²Rheumatology., Hospital Universitario Santiago de Compostela, Santiago de Compostela, Spain, ³³Rheumatology., Hospital Cabueñes, Gijón, Gijón, Spain, ³⁴Rheumatology., Hospital Lucus Augusti Lugo, Lugo, Spain, ³⁵Rheumatology., Hospital San Pedro Alcantara Caceres, Caceres, Spain, ³⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca. Murcia, Murcia, Spain, ³⁷Rheumatology., Fundación Jimenez Díaz. Madrid, Madrid, Spain, ³⁸Rheumatology., Hospital 12 de Octubre. Madrid, Madrid, Spain, ³⁹Rheumatology Unit, Hospital Universitario Fundación Alcorcón. Madrid, Alcorcon. Madrid, Spain, ⁴⁰Ophthalmology, Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴¹Rheumatology., Hospital de Mérida, Mérida, Spain, ⁴²Hospital Germans Trias i Pujol. Badalona, Barcelona, Spain, ⁴³Rheumatology, Hospital de Ferrol. A Coruña, A Coruña, Spain, ⁴⁴Hospital Universitario Miguel Servet. Zaragoza, Zaragoza, Spain
Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].